Table 1 Patient characteristics (n = 161)

 Median (range)

47.4 (25.4–87.3)

51.7 (27.6–87.3)

46.4 (25.4–68.5)

46.9 (27.6–74.7)

 Mean ± SD

48.1 ± 11.0

51.7 ± 13.5

46.3 ± 10.1

47.5 ± 10.4

  <  50

96 (59.6)

13 (46.4)

12 (57.1)

71 (63.4)

  ≥ 50

65 (40.4)

15 (53.6)

9 (42.9)

41 (36.6)

 T1 (≤ 2 cm)

18 (11.2)

3 (10.7)

1 (4.8)

14 (12.5)

 T2 (>  2 cm, ≤ 5 cm)

132 (82.0)

24 (85.7)

18 (85.7)

90 (80.4)

 T3 (>  5 cm)

11 (6.8)

1 (3.6)

2 (9.5)

8 (7.1)

 Negative

34 (21.1)

6 (21.4)

5 (23.8)

23 (20.5)

 Positive

127 (78.9)

22 (78.6)

16 (76.2)

89 (79.5)

 IDC

145 (90.1)

22 (78.6)

19 (90.5)

104 (92.9)

 IDC + DCIS

12 (7.5)

4 (14.3)

1 (4.8)

7 (6.2)

 Others

4 (2.5)

2 (7.1)

1 (4.8)

1 (0.9)

 in situ

2 (1.3)

1 (3.6)

1 (5.0)

0 (0)

 I

17 (11.3)

4 (14.3)

1 (5.0)

12 (11.8)

 II

77 (51.3)

16 (57.1)

13 (65.0)

48 (47.1)

 III

54 (36.0)

7 (25.0)

5 (25.0)

42 (41.2)

 Missing

11

0

1

10

 Luminal

53 (32.9)

9 (32.1)

11 (52.4)

33 (29.5)

 Luminal HER2

41 (25.5)

8 (28.6)

3 (14.3)

30 (26.8)

 HER2

21 (13.0)

5 (17.9)

3 (14.3)

13 (11.6)

 TNBC

46 (28.6)

6 (21.4)

4 (19.0)

36 (32.1)

 Anthracycline-based

33 (20.5)

5 (17.9)

7 (33.3)

21 (18.8)

 Taxane-based

14 (8.7)

2 (7.1)

2 (9.5)

10 (8.9)

 Combined anthracycline and taxane

65 40.4)

10 (35.7)

7 (33.3)

48 (42.9)

 HER2 targeting agent contained

46 (28.6)

9 (32.1)

5 (23.8)

32 (28.6)

 Others

3 (1.9)

2 (7.1)

0 (0)

1 (0.9)

Median (range)

34.7 (5.3–118.9)

23.5 (5.3–105.5)

39.3 (7.7–105.6)

35.8 (6.9–118.9)

Mean ± SD

44.9 ± 31.8

36.1 ± 29.5

49.3 ± 34.2

46.2 ± 31.9